Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir
about
Drug interactions between antiretrovirals and drugs used to treat benign prostatic hyperplasia/lower urinary tract symptoms.Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice.Cigarette smoking in the HIV-infected population.Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.Differences in Methadone Metabolism by CYP2B6 VariantsUse of antineoplastic agents in patients with cancer who have HIV/AIDS.Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and MetabolismPharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai AdultsRapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men.Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevanceDevelopment and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma.Role of cytochrome P4502B6 in methadone metabolism and clearance.The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavirChanges in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach.Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.Interactions between antifungal and antiretroviral agents.Clinically significant drug interactions with newer antidepressants.Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems.Induction of cytochrome P450 enzymes: a view on human in vivo findings.Drug interactions between antiretrovirals and hormonal contraceptives.Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities.Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.Single-dose pharmacokinetics of bupropion hydrobromide and metabolites in healthy adolescent and adult subjects.Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy.Dose-related reduction in bupropion plasma concentrations by ritonavir.Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients.Current Concepts in Methadone Metabolism and Transport.
P2860
Q30249162-13686D46-E911-45E5-B5FA-1509BBE39FB5Q34217306-520BFF31-4AEE-4A07-B266-69277CBB88D2Q35095054-C81E0563-AF4A-4A06-B8F8-81169F6DB805Q35579558-3E02275F-5667-4520-87E2-726A2D77BA9EQ35745266-4A6279F3-5FF2-46FE-875F-86A1697B25C3Q35932561-109B1E06-8C05-49BC-BD86-D7A10A73DB69Q36342286-009CCD8B-7768-4ADA-B72A-88CC3F605FE5Q36359372-47549351-C2CD-4A59-BA19-08F704535442Q36468142-F6AEE8F7-61D9-45B6-AE4B-6661ECA147ABQ36641884-93579943-6BAC-4F68-8F26-E930CCE669A8Q36652680-489D2991-3668-4410-A5C8-2CA631737C88Q36657589-C0A1B95D-DD78-4D7E-8439-225D66CD3F41Q36796793-75BC34F3-F864-48F3-902C-6841C86DCEE1Q37094439-26197536-706C-4551-83B7-5248E1565F1DQ37193089-7C1CE341-72E9-4997-A785-5F591D8D48D9Q37317619-DE8E4E5F-117C-4737-BAAB-1854D17A9652Q37325606-4586AC0B-33E0-45FD-9B78-28C47507C20AQ37378110-30C2B680-3AF6-4096-BDD7-62CA0347B30CQ37669678-A5199EF5-0CDD-4180-A0AA-779E35B6CC8FQ37719545-AD8F257A-F703-48B1-837C-0ACBAA4B070FQ37968621-6DDB47B5-E0BB-467A-B220-37103CC83A3FQ38028549-CA63897D-897D-497E-9DB8-3192C437585EQ38057372-660AA41A-0814-4D03-8ED8-01147516F66BQ38083080-701179DB-954E-4CF9-9F75-01381D20B532Q38815352-628C5213-F8FF-426F-A152-520D6F67B0F0Q38928302-CC164BB9-CB5D-4D12-B42D-CB0AD6811283Q39158102-CECF4E7B-2193-4585-B99E-04E3808A6C23Q39802397-036D1275-FFF1-41B7-8592-903A0CCF56E9Q42276687-27B97D20-5364-4620-A3D9-A650906927E0Q43059456-DCB268E4-5305-45C9-A975-6275BCD5D035Q43204477-4AF6CB3E-B0A9-490A-B21B-05C1F9ACE1FAQ43254867-CB57DA69-E739-4E66-A55E-BFBBC0477153Q50682107-FEFD7CAC-310B-4BC1-AA8C-A43EBD4D6DAB
P2860
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir
@ast
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir
@en
type
label
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir
@ast
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir
@en
prefLabel
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir
@ast
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir
@en
P2093
P2860
P356
P1476
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir
@en
P2093
Darain Mitchell
Evan D Kharasch
Rebecka Coles
Roberto Blanco
P2860
P304
P356
10.1128/AAC.01600-07
P407
P577
2008-02-19T00:00:00Z